New: 2026 Peptide Research Digest is live. Read the report
Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates Research-backed content PubMed cited sources Medically reviewed by experts Quarterly content updates

Retatrutide

Weight Loss

Triple Agonist

Calculate Reconstitution

Overview Profile

A novel triple hormone receptor agonist (GLP-1, GIP, and Glucagon) demonstrating unprecedented weight loss results in clinical trials.

Primary Target Benefits

weight lossmetabolism

Research Notice: This profile is informational. Peptides are widely sold as research chemicals and many are not FDA-approved for human consumption. Always consult local regulations and a medical provider before proceeding.

Quick Research Facts

Standard Dose Observation

1000-12000 mcg

Typical Available Vial Sizes

5mg10mg15mg

Development / Research Status

Phase III

More in Weight Loss

Semaglutide

GLP-1 Receptor Agonist

View Profile

Tirzepatide

Dual GIP and GLP-1 Receptor Agonist

View Profile

AOD-9604

Advanced Obesity Drug 9604

View Profile